US pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccineThe US government has selected a potential vaccine from Sanofi and GlaxoSmithKline for its Operation Warp Speed COVID-19 Share XUS pays $2.1bn to Sanofi/GSK for 100 million doses of COVID-19 vaccinehttps://pharmaphorum.com/news/us-pays-sanofi-gsk-100-million-doses-covid-19-vaccine/
Gilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisitionGilead has blamed a $3.3 billion loss in Q2 on its acquisition of immune-oncology company Forty Seven – Share XGilead loses $3.3bn in Q2, blaming COVID-19 and cancer drugs firm acquisitionhttps://pharmaphorum.com/news/gilead-blames-3-3-billio/
Study puts Jardiance in hot pursuit of AZ’s Farxiga in heart failureThe FDA’s approval of AstraZeneca’s SGLT2 inhibitor Farxiga in heart failure was a first for the class, but Share XStudy puts Jardiance in hot pursuit of AZ’s Farxiga in heart failurehttps://pharmaphorum.com/news/study-puts-jardiance-in-hot-pursuit-of-azs-farxiga-in-heart-failure/
Coronavirus pharma news roundup – 31/07/20Vaccines, AI-driven drug discovery and llamas all hit the headlines this week as the search for a way Share XCoronavirus pharma news roundup – 31/07/20https://pharmaphorum.com/views-and-analysis/coronavirus-pharma-news-roundup-31-07-20/
Brits more comfortable sharing data with pharma since COVID-19 – surveyNew research from MHP Health and ComRes looks at what impacts COVID-19 has had on the public’s health Share XBrits more comfortable sharing data with pharma since COVID-19 – surveyhttps://pharmaphorum.com/views-and-analysis/brits-data-sharing-pharma-covid-19-survey/
Coronavirus pharma news roundup – 24/07/20With coronavirus vaccine trials finally showing positive results, analysts are starting to wonder what access challenges might lie Share XCoronavirus pharma news roundup – 24/07/20https://pharmaphorum.com/views-analysis-market-access/coronavirus-pharma-news-roundup-24-07-20/
Vaccines trials in the COVID-19 era and tech’s role in speeding studiesOverview The COVID-19 outbreak has exposed the challenges pharmaceutical companies face as they race to develop a coronavirus Share XVaccines trials in the COVID-19 era and tech’s role in speeding studieshttps://pharmaphorum.com/r-d/vaccines-trials-covid-19-coronavirus/
The COVID-19 coronavirus and pharma and biotech continuity planningOverview Pharmaceutical and biotech companies around the globe are working with Governments to address the COVID-19 outbreak, from Share XThe COVID-19 coronavirus and pharma and biotech continuity planninghttps://pharmaphorum.com/r-d/the-potential-impact-of-coronavirus-covid-19-for-global-pharma-and-biotech-continuity/
Navigating new frontiers: Ways to find space in the future RA marketOverview Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 Share XNavigating new frontiers: Ways to find space in the future RA markethttps://pharmaphorum.com/r-d/navigating-new-frontiers-ways-to-find-space-in-the-future-ra-market/
J+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERFC+, Pharma Forecasting Software has been upgraded Share XJ+D FORECASTING MAKES THE PHARMA FORECASTING EXPERIENCE EVEN BETTERhttps://pharmaphorum.com/partner-content/jd-forecasting-makes-the-pharma-forecasting-experience-even-better/
PPE for Infection Control Market Will Touch $17.1 Billion By 2026Global Market Insights, Inc., report forecasts the personal protective equipment for infection control industry to grow at a Share XPPE for Infection Control Market Will Touch $17.1 Billion By 2026https://pharmaphorum.com/partner-content/ppe-for-infection-control-market-will-touch-17-1-billion-by-2026/
Dermatology Devices Market Size Will Achieve 11.9% CAGR From 2019 To 2025The global dermatology devices market size is expected to reach USD 20 billion by 2025, at a CAGR of Share XDermatology Devices Market Size Will Achieve 11.9% CAGR From 2019 To 2025https://pharmaphorum.com/partner-content/dermatology-devices-market-size-will-achieve-11-9-cagr-from-2019-to-2025/
